Filing Flows › Mirum Pharmaceuticals (MIRM) › Q1 2026
Mirum Pharmaceuticals (MIRM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Mirum Pharmaceuticals (MIRM) reported revenue of $160M for the first quarter 2026 (Q1 2026), +43% from a year earlier and +7% from the quarter before. Operating margin was -493.8%, net loss $790M (494.2% of revenue).
Mirum Pharmaceuticals, Q1 2026: revenue $160M (+43% year over year), operating margin -493.8%, net loss $790M, operating cash flow −$229M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $160M | +7% | +43% |
| Operating profit | −$789M | — | — |
| Net earnings | −$790M | — | — |
| Operating cash flow | −$229M | -3871% | — |
What changed
Revenue was $159.9M in Q1 2026, up 43% year over year and up 7% from the previous quarter. Livmarli was the largest line at 71% of revenue. Livmarli added $40.6M year over year (up 55%), 84% of the total change.
Operating costs exceeded revenue by $789.5M, an operating margin of -493.8%. Total costs grew 649% against revenue growth of 43%. The fastest-growing cost line was Other operating costs (+2595%). The quarter ended with a net loss of $790.2M, wider than the previous quarter's $5.7M loss.
Operating cash flow was −$228.8M. Non-cash charges added back $6.9M of depreciation and amortization and $36.2M of share-based compensation. Working capital and other items added $518.3M. Capital expenditures of $664K exceeded it, leaving free cash flow of −$229.4M.
Questions
What was Mirum Pharmaceuticals' revenue in the first quarter 2026?
Mirum Pharmaceuticals (MIRM) reported revenue of $160M for the first quarter 2026 (Q1 2026), +43% from a year earlier and +7% from the quarter before.
Was Mirum Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $789M (-493.8% of revenue) and net loss $790M.